September 28, 2016 5:20 PM ET

Pharmaceuticals

Company Overview of Hospira Inc.

Company Overview

Hospira, Inc. provides injectable drugs and infusion technologies to develop, manufacture, distribute, and market products worldwide. The company operates through Americas, EMEA, and APAC segments. It provides specialty injectable pharmaceuticals, which include approximately 200 injectable generic drugs in multiple dosages and formulations; and proprietary specialty injectables, such as Precedex, a proprietary drug for sedation. The company’s specialty injectable pharmaceuticals also comprise Biosimilars that include Retacrit, an EPO, which is primarily used in the treatment of anemia in dialysis and in certain oncology applications; Nivestim, a biosimilar filgrastim used for the treatment o...

275 North Field Drive

Lake Forest, IL 60045

United States

Founded in 2003

19,000 Employees

Phone:

224-212-2000

Key Executives for Hospira Inc.

Chief Financial Officer and Senior Vice President of Finance
Age: 59
Senior Vice President of Operations
Age: 48
President of Hospira Medical Devices
Age: 51
President of US Operations
Chief Scientific Officer and Senior Vice President
Age: 47
Compensation as of Fiscal Year 2016.

Hospira Inc. Key Developments

Pfenex Inc. Terminates Agreement with Hospira Inc

On February 9, 2015, Pfenex Inc. (the Company) and Hospira Inc. (together with its affiliates, Pfizer), entered into a Development and License Agreement (the Collaboration Agreement) pursuant to which the Company and Pfizer agreed to collaboratively develop the Company's biosimilar candidate to Lucentis, PF582 (the Product) for retinal conditions. Under the terms of the Collaboration Agreement, Pfizer received exclusive licenses and rights and assumed responsibility for the sale, marketing, promotion and commercialization of the Product, and was obligated to use commercially reasonable efforts to sell, market, promote and commercialize the Product in certain named major markets. In consideration for the exclusive license and other rights contained in the Collaboration Agreement, the Company was eligible to receive up to $342 million in one-time payments, including $51 million that was received once the Collaboration Agreement received U.S. antitrust approval, up to $291 million upon the successful achievement of certain pre-commercial and commercial milestones, and double digit escalating royalties on annual sales of the Product. Pfenex will regain the full rights to PF582 following Pfizer's strategic review of the current therapeutic focus of its biosimilar pipeline. To that effect, on August 5, 2016, the Company, Hospira Bahamas Biologics Ltd., and Hospira Inc., entered into a Termination Agreement (the Termination Agreement) pursuant to which the parties agreed to terminate the Collaboration Agreement. Such termination of the Collaboration Agreement was effective as of August 5, 2016 (the Termination Date). Under the terms of the Termination Agreement, the Company regained exclusive, worldwide rights for, and the parties terminated their collaboration in regard to, the development, manufacture and commercialization of the Product. The Termination Agreement further provides for the grant by Pfizer to the Company of a perpetual license under intellectual property rights developed by Pfizer under the Collaboration Agreement, the transfer from Pfizer to the Company of know-how and regulatory materials relating to the Product that were generated by Pfizer under the Collaboration Agreement, and the formation of a transition committee with equal representation to establish and oversee the implementation of a transition plan. In addition, the Termination Agreement provides for a mutual release of claims and restricts Pfizer and its affiliates from developing or commercializing a competing product (in relation to the Product) during the period of 12 months following the Termination Date.

Teva Pharmaceutical Industries Ltd. Announces Favorable Court Ruling in TREANDA Patent Infringement Litigation Against Hetero Usa, Inc., Innopharma Inc., Hospira Inc., Sagent Pharmaceuticals Inc., and Accord Healthcare Inc

Teva Pharmaceutical Industries Ltd. announced that the United States District Court for the District of Delaware has ruled in favor of Teva in the Company’s patent infringement lawsuit against Hetero USA, Inc., InnoPharma Inc., Hospira Inc., Sagent Pharmaceuticals Inc., and Accord Healthcare Inc., regarding Teva’s TREANDA (bendamustine hydrochloride) for Injection. At trial, the defendants alleged that certain claims of U.S. Patents 8,436,190; 8,609,863; 8,791,270; and 8,895,756, listed in the Orange Book for TREANDA®, are invalid. The defendants had previously stipulated to infringement of certain claims of these patents.

Hospira Launches LifeCare PCA® 7.0 Infusion System

Hospira announced the launch of the LifeCare PCA® 7.0 Infusion System. As the first patient-controlled analgesia (PCA) infusion pump to offer electronic medical record (EMR) integration (also known as I.V.-EMR interoperability), LifeCare PCA 7.0 is a next-generation infusion system. It enables device auto-programming and streamlines documentation of infusion data to help improve the safety and efficiency of pain management medication administration. It's PCA pump with integrated bar code identification of prefilled and pharmacy-filled drug vials, substantially eliminating the potential for drug and concentration errors at the bedside. Medication errors affect 1.5 million people and cost $21 billion annually, and the EMR integration and bar-code technology help give health care providers confidence that the right drug is being administered to the patient at the right dose and in the right concentration. The LifeCare PCA 7.0 system has been granted clearance by the U.S. Food and Drug Administration (FDA) with enhanced cybersecurity protections. It features new security options, which include: hospital-configured device passwords and enhanced protection of customer network security settings, helping to prevent unauthorized access, automatic detection and closure of unused network communications ports, limiting remote access points to the device and network and updated communications engine technology, including removal of telnet service, thereby eliminating remote administrator, or root access, to the pump. Additionally, through Hospira MedNetv6.1 next-generation safety software, LifeCare PCA 7.0 includes new alarm-forwarding functionality.

Similar Private Companies By Industry

Company Name Region
21st Century Animal Health United States
3 Buds' Organics LLC United States
4P Therapeutics LLC United States
60° Pharmaceuticals, LLC United States
7 Oaks Pharmaceutical Corp. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Hospira Inc., please visit www.hospira.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.